We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Maintaining the B Cell Population Requires Receptor Harmony

By LabMedica International staff writers
Posted on 12 Nov 2008
Immune system researchers have found that the number of immune B cells is maintained at an optimal level through the harmonious activity of two signaling molecules.

Investigators at the University of Pennsylvania School of Medicine (Philadelphia, PA, USA) focused their attention on two B cell surface receptors: the B cell antigen receptor (BCR) and the BLyS receptor 3 (BR3).

Signals propagated through the B cell antigen receptor (BCR) are vital for the development and survival of B cells in both the bone marrow and the periphery. More...
These signals not only guide maturation and activation but also affect the removal of potentially self-reactive B cells.

The tumor necrosis factor (TNF) super family of cytokines includes both soluble and membrane-bound proteins that regulate immune responses. BLyS (B lymphocyte stimulator), a member of the human TNF family, induces B cell proliferation and immunoglobulin secretion. BLyS expression on human monocytes can be upregulated by interferon-gamma. Soluble BLyS functions as a potent B cell growth factor in co-stimulation assays.

Results published in two papers, one in the October 1, 2008, online edition of the  Proceedings of the [U.S.] National Academy of Sciences (PNAS) and the other in the November 2, 2008, online edition of the journal Nature Immunology, presented a clear picture of the interaction between the two types of receptor. "One receptor sends signals to the cell nucleus that says, ‘yes stay alive, the body needs more B cells,' while the other says ‘wait a minute, be careful which B cells are allowed to live',” said senior author Dr. Michael P. Cancro, professor of pathology and laboratory medicine at the University of Pennsylvania School of Medicine.

"There is a steady state number of B cells that is considered normal for humans, and we found that molecular cross talk between two receptors on the surface of B cells balances the need to have enough B cells to make good immune responses, while at the same time guarding against autoimmunity, ” said Dr. Cancro.

Related Links:
University of Pennsylvania School of Medicine




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Prefilled Tubes
Prefilled 5.0ml Tubes
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Nian Sun has spent years perfecting a device that he believes could change the way diseases are detected. (Photo courtesy of Alyssa Stone/Northeastern University)

Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air

Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers

Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.